HLA-C and cancer: Various factors, including irreversible T cell exhaustion, oncogene mutations, dysfunction of major histocompatibility complex (MHC), tumor mutational burden, neoantigen, and immune infiltrate, have been suggested as etiologies of resistance.[17, 18, 46] This situation can be solved by enhancing T cell priming, increasing T cell infiltration, or improving immunosuppressive TME.[47, 48, 49] Immune checkpoint proteins are considered potent targets in cancer immunotherapy.